Advanced Cancer Therapies

Clinical Trials

 

The physicians and staff at Advanced Cancer Therapies and Wichita Urology Group devote a portion of their time to the future by participating in clinical research to discover improved treatment options and more beneficial therapies for urological cancers. This involvement gives you access to advanced procedures and treatment options that might not otherwise be available. If you are interested in participating in a clinical trial, one of our urologists can determine if you qualify. Once the clinical trial process begins, you will be closely monitored and informed of all benefits and potential risks associated with the trial. Patients can opt out of the trial at any time.

Please feel free to talk with your physician if you are interested in learning more about one of our trials.

When You Join a Research Trial

  • You help bring new methods of preventing, diagnosing and treating diseases, including cancer.
  • Have an opportunity to learn more about your cancer with more individualized care.
  • Receive tests and study medication at no cost.

 

Currently Enrolling

Prostate Cancer - EMBARK

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

For more information please visit clinicaltrials.gov

Prostate Cancer - ATLAS Janssen

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Investigator)
  • Primary Purpose: Treatment

Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

For more information please visit clinicaltrials.gov

Prostate Cancer - Trumpet Registry

Study Type: Observational

Study Design:

  • Observational Model: Cohort
  • Time Perspective: Prospective

Official Title: A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States

For more information please visit clinicaltrials.gov

Prostate Cancer- Janssen- BSPCR

Official Title: Analyses of Matched plasma FFPE Tumor Samples to Detect Genetic Changes Associated with Metastatic prostate Cancer

Prostate Cancer- Myovant Hero

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Official Title: HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

For more information please visit clinicaltrials.gov

Prostate Cancer- Innocrin

Study Type: Interventional

Study Design:

  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Masking Description: Open Label
  • Primary Purpose: Treatment

Official Title: A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

For more information please visit clinicaltrials.gov

Prostate Cancer- MiCheck

Official Title: Prospective Prostate Cancer Study

 

Ongoing Studies – Not Enrolling

Prostate Cancer - TAK-385

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Single Group Assignment
  • Masking: Open Label
  • Primary Purpose: Treatment

Official Title: A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer

For more information please visit clinicaltrials.gov

Prostate Cancer - PROCEED

Study Type: Observational

Study Design:

  • Observational Model: Cohort
  • Time Perspective: Prospective

Official Title: A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cance

For more information please visit clinicaltrials.gov 

Prostate Cancer - Genomic Health

Study Type: Confirmatory Diagnostic

Study Design: A prospective Multicenter Observational Trial

Official Title: A prospective multicenter observational trial to assess persistence on active surveillance while using the Oncotype DX prostate cancer assay

Prostate Cancer- EXPEC Janssen

Official Title: Prospective Evaluation of the Incidence of Extraintestinal Pathogenic Escherichia coli (ExPEC) Disease, O-serotype Prevalence of ExPEC, ExPEC Case Defenition, and Health Outcomes Following Transrectal Ultrasound-Guided Prostate Needle Biopsy (TRUS-PNB)

Renal Cell Carcinoma - ATLAS

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Primary Purpose: Prevention

Official Title: Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC

For more information please visit clinicaltrials.gov

Prostate Cancer - Bayer REASSURE

Study Type: Observational

Study Design:

  • Observational Model: Cohort
  • Time Perspective: Prospective

Official Title: Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

For more information please visit clinicaltrials.gov

Prostate Cancer - PROSPER

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer

For more information please visit clinicaltrials.gov

Prostate Cancer - ARAMIS

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

For more information please visit clinicaltrials.gov

Prostate Cancer - Chruchill Zytiga / Zytiga

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Open Label
  • Primary Purpose: Treatment

Official Title:   A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY

For more information please visit clinicaltrials.gov

BPH / Nocturia - Equinoc / Vantia BPH Nocturia

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title:   A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)

For more information please visit clinicaltrials.gov

 

Learn More About Clinical Trials

Speak with your provider or call our research office at (316) 636-6141.